Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity (Details Narrative)

v3.21.2
Stockholders’ Equity (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 20, 2021
Jun. 16, 2021
Feb. 24, 2021
Aug. 31, 2020
Mar. 31, 2021
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
StockholdersEquityLineItems [Line Items]                
Prepaid Expense           $ 107,193    
Stock Issued During Period, Value, New Issues         $ 9,875,550      
Proceeds from Issuance of Private Placement           $ 9,875,550  
Class of Warrant or Right, Exercise Price of Warrants or Rights           $ 10.66    
Warrants and Rights Outstanding, Maturity Date           Feb. 16, 2023    
Preferred stock, shares outstanding           0   0
Preferred stock, shares issued           0   0
Private Placement [Member]                
StockholdersEquityLineItems [Line Items]                
Stock Issued During Period, Shares, New Issues     1,321,132          
Stock Issued During Period, Value, New Issues     $ 10,200,000          
Proceeds from Issuance of Private Placement     $ 9,900,000          
Ocuphire Agreement [Member] | Ocuphire Pharma Inc [Member]                
StockholdersEquityLineItems [Line Items]                
Stock Issued During Period, Shares, New Issues   44,689            
Sales Agreement [Member]                
StockholdersEquityLineItems [Line Items]                
Aggregate offering price $ 30,000,000.0              
Gross proceeds of sales, percent 3.00%              
Restricted Stock [Member]                
StockholdersEquityLineItems [Line Items]                
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period       324,360        
Consultants [Member]                
StockholdersEquityLineItems [Line Items]                
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross           17,800    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights           180,000    
[custom:CommonStockOptionAndWarrantIssuedValue]           $ 797,216    
Employees [Member] | State and Local Jurisdiction [Member]                
StockholdersEquityLineItems [Line Items]                
Shares Issued, Shares, Share-based Payment Arrangement, Forfeited           6,043    
Employees [Member] | Restricted Stock [Member]                
StockholdersEquityLineItems [Line Items]                
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period           37,500    
Placement Agent [Member] | Private Placement [Member]                
StockholdersEquityLineItems [Line Items]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights     79,268          
Class of Warrant or Right, Exercise Price of Warrants or Rights     $ 9.30          
Warrants and Rights Outstanding, Maturity Date     Feb. 24, 2023